Frequency and predictors of complications in neurological surgery: national trends from 2006 to 2011.
John D Rolston, Seunggu J Han, Catherine Y Lau...
https://pubmed.ncbi.nlm.nih.gov/24266542/Actively Recruiting
Led by Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta · Updated on 2026-02-19
200
Participants Needed
2
Research Sites
82 weeks
Total Duration
Researchers are studying rare brain tumors, which vary in their characteristics and are uncommon, affecting fewer than 6 in 100,000 people yearly. The goal is to improve and standardize how care is given to patients with these tumors by using Artificial Intelligence AI and Machine Learning ML to better predict surgical outcomes and enhance patient care. This study is conducted in both retrospective and prospective phases to gather important clinical, cognitive, and psychological information. The study involves adult patients with rare brain tumors undergoing craniotomy. Participants will receive an early neuro-cognitive rehabilitation program using the RehaCom software at home. This program is designed to improve cognitive functions potentially affected by surgery, with sessions lasting about 30 to 40 minutes twice a week for eight weeks. The retrospective phase uses existing data to develop predictive models, while the prospective phase collects new data at multiple time points before and after surgery. Participants will be evaluated through various clinical and cognitive tests at baseline, discharge, three months, and twelve months after surgery. These include neurological assessments, imaging, cognitive function tests, and quality of life questionnaires. The study tracks surgical outcomes, cognitive recovery, and psychological well-being to develop better care models. Approximately 200 adults will take part, with ongoing monitoring to improve treatment pathways and patient quality of life.
CONDITIONS
SIMPLIFication of Care Pathways for Patients With Rare Brain Tumors Through Artificial Intelligence
G
GIORGIA CAMARDA, Master's degree
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Lead Sponsor
ASL 1 Avezzano Sulmona L'Aquila
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 8 weeks
Participants undergo craniotomy surgery for rare brain tumors and receive a personalized neuro-cognitive rehabilitation program using the RehaCom software at home to enhance or recover cognitive functions affected by surgery.
Twice weekly rehabilitation sessions at home
Duration - Up to 12 months post-surgery
Participants are assessed with clinical, cognitive, and psychological evaluations at discharge, 3 months, and 12 months post-surgery to monitor recovery and outcomes.
Visits at discharge, 3 months, and 12 months post-surgery
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
John D Rolston, Seunggu J Han, Catherine Y Lau...
https://pubmed.ncbi.nlm.nih.gov/24266542/Paolo Ferroli, Morgan Broggi, Silvia Schiavolin...
https://pubmed.ncbi.nlm.nih.gov/26621412/Elina Reponen, Hanna Tuominen, Miikka Korja
https://pubmed.ncbi.nlm.nih.gov/25046789/Oscar Lopez-Nunez, Rita Alaggio, Ivy John...
https://pubmed.ncbi.nlm.nih.gov/33572349/Morgan Broggi, Costanza Zattra, Paolo Ferroli
https://pubmed.ncbi.nlm.nih.gov/29629232/Adomas Bunevicius, Sarunas Tamasauskas, Vytenis Deltuva...
https://pubmed.ncbi.nlm.nih.gov/24254135/Lisa Millgård Sagberg, Christina Drewes, Asgeir S Jakola...
https://pubmed.ncbi.nlm.nih.gov/27315026/Silvia Schiavolin, Alberto Raggi, Chiara Scaratti...
https://pubmed.ncbi.nlm.nih.gov/29502163/Joeky T Senders, Patrick C Staples, Aditya V Karhade...
https://pubmed.ncbi.nlm.nih.gov/28986230/Feng-Lei Fan, Jinjun Xiong, Mengzhou Li...
https://pubmed.ncbi.nlm.nih.gov/35573928/Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Lead Sponsor
ASL 1 Avezzano Sulmona L'Aquila
Collaborating Sponsor